James Byrne, VP Site for Ipsen Manufacturing Ireland, discusses the strategic importance of the Ireland site as the sole provider of peptides for…

Marc de Garidel reveals how 2015 has been Ipsen's best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US…

Mexico is a key market for Ipsen to consolidate its footprint in the Americas. The recently appointed general manager and the medical director of the…

Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the…

In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a…

Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are…

When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How…

Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and…

Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in…

Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest…

As the G5 brings together five very different companies - Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier - could you explain the origin behind the…